Cutler Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,500
| Closed | -$88K | – | 3960 |
|
|
2023
Q4 | $88K | Buy |
1,500
+460
| +44% | +$25.9K | 0.01% | 1124 |
|
|
2023
Q3 | $45K | Sell |
1,040
-100
| -9% | -$3.57K | ﹤0.01% | 1565 |
|
|
2023
Q2 | $41K | Sell |
1,140
-100
| -8% | -$4.12K | 0.01% | 1418 |
|
|
2023
Q1 | $46K | Sell |
1,240
-4,360
| -78% | -$196K | ﹤0.01% | 1412 |
|
|
2022
Q4 | $253K | Buy |
5,600
+4,780
| +583% | +$309K | 0.02% | 676 |
|
|
2022
Q3 | $57K | Sell |
820
-2,730
| -77% | -$202K | ﹤0.01% | 1801 |
|
|
2022
Q2 | $238K | Buy |
+3,550
| New | +$226K | 0.02% | 913 |
|
|
2022
Q1 | – | Sell |
-8,367
| Closed | -$856K | – | 6278 |
|
|
2021
Q4 | $1.23M | Sell |
8,367
-11,976
| -59% | -$1.86M | 0.05% | 388 |
|
|
2021
Q3 | $3.6M | Buy |
+20,343
| New | +$3.27M | 0.16% | 135 |
|
|
2021
Q1 | – | Sell |
-1,268
| Closed | -$251K | – | 6486 |
|
|
2020
Q4 | $278K | Buy |
1,268
+105
| +9% | +$22.7K | 0.01% | 905 |
|
|
2020
Q3 | $193K | Sell |
1,163
-1,141
| -50% | -$156K | 0.01% | 929 |
|
|
2020
Q2 | $263K | Buy |
+2,304
| New | +$223K | 0.02% | 726 |
|
|
2020
Q1 | – | Sell |
-5,906
| Closed | -$530K | – | 4831 |
|
|
2019
Q4 | $761K | Buy |
5,906
+3,006
| +104% | +$290K | 0.05% | 325 |
|
|
2019
Q3 | $225K | Sell |
2,900
-4,450
| -61% | -$418K | 0.02% | 654 |
|
|
2019
Q2 | $757K | Buy |
+7,350
| New | +$572K | 0.07% | 250 |
|
|
2019
Q1 | – | Sell |
-801
| Closed | -$54.5K | – | 4928 |
|
|
2018
Q4 | $33K | Sell |
801
-8,599
| -91% | -$343K | ﹤0.01% | 1756 |
|
|
2018
Q3 | $442K | Buy |
+9,400
| New | +$523K | 0.03% | 512 |
|
|
2018
Q2 | – | Sell |
-1,206
| Closed | -$45.5K | – | 5080 |
|
|
2018
Q1 | $37K | Buy |
+1,206
| New | +$33.5K | ﹤0.01% | 1886 |
|
|
2017
Q4 | – | Sell |
-20,700
| Closed | -$321K | – | 6185 |
|
|
2017
Q3 | $242K | Buy |
20,700
+12,460
| +151% | +$72.1K | 0.01% | 1054 |
|
|
2017
Q2 | $30K | Sell |
8,240
-59,973
| -88% | -$230K | ﹤0.01% | 3013 |
|
|
2017
Q1 | $354K | Buy |
68,213
+61,873
| +976% | +$339K | 0.01% | 822 |
|
|
2016
Q4 | $30K | Buy |
6,340
+1,100
| +21% | +$5.98K | ﹤0.01% | 3067 |
|
|
2016
Q3 | $34K | Buy |
5,240
+1,100
| +27% | +$5.85K | ﹤0.01% | 2869 |
|
|
2016
Q2 | $22K | Buy |
4,140
+1,000
| +32% | +$15.9K | ﹤0.01% | 3277 |
|
|
2016
Q1 | $67K | Sell |
3,140
-900
| -22% | -$20.1K | ﹤0.01% | 2018 |
|
|
2015
Q4 | $127K | Buy |
+4,040
| New | +$143K | 0.01% | 1561 |
|
Other funds holding MRTX
Cutler Group's MRTX Position: Q1 2024 in Review
Cutler Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,500 shares — an estimated $88K sold.
Cutler Group first reported a position in MRTX in Q4 2015 and held it in 26 quarters. The position peaked at $3.6M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Cutler Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Cutler Group sold 1,500 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $88K.
- Cutler Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 26 quarters.
- Cutler Group's Mirati Therapeutics, Inc. Common Stock position peaked at $3.6M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.